These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15262038)

  • 1. Utilization of eptifibatide for treatment of severe dissections as a bail-out procedure.
    Latsch A; Suselbeck T; Muth N; Poerner T; Baumbach A; Pfleger S; Borggrefe M; Haase KK
    Int J Cardiol; 2004 Aug; 96(2):229-33. PubMed ID: 15262038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK; Mahrholdt H; Schröder S; Baumbach A; Oberhoff M; Herdeg C; Karsch KR
    Am Heart J; 1999 Feb; 137(2):234-40. PubMed ID: 9924156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
    Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of adjunctive eptifibatide therapy with percutaneous coronary intervention for acute myocardial infarction.
    Lev EI; Kornowski R; Teplisky I; Hasdai D; Rechavia E; Shor N; Battler A; Assali AR
    Int J Cardiovasc Intervent; 2005; 7(1):41-5. PubMed ID: 16019614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: a 30-day follow-up study.
    Kaul U; Gupta RK; Haridas KK; Ramesh SS; Sethi KK; Singh B; Agarwal R; Yadave RD; Ghose T; Sapra RR; Bajaj R; Shahi M; Bhagwat A; Kumar P; Mathews OP; Soni PK;
    Catheter Cardiovasc Interv; 2002 Dec; 57(4):497-503. PubMed ID: 12455085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome of patients undergoing low aggressive angioplasty combined with brachytherapy and short-term dual antiplatelet therapy for in-stent restenosis.
    Di Pede F; Buja P; Millosevich P; Grassi G; Celestre M; Zuin G; Marchetti C; Pizzi G; Antonello M; Bindoni L; Raviele A
    J Cardiovasc Med (Hagerstown); 2006 Oct; 7(10):731-6. PubMed ID: 17001233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial.
    Labinaz M; Kaul P; Harrington RA; Chang WC; Kleiman NS; Simoons ML; Boersma E; Akkerhuis KM; Califf RM; Armstrong PW;
    Can J Cardiol; 2004 Jun; 20(8):773-8. PubMed ID: 15229770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of high-dose intravenous eptifibatide as an adjunct to internal carotid artery angioplasty and stent placement: a prospective registry.
    Qureshi AI; Siddiqui AM; Hanel RA; Xavier AR; Kim SH; Kirmani JF; Boulos AS; Hopkins LN
    Neurosurgery; 2004 Feb; 54(2):307-16; discussion 316-7. PubMed ID: 14744276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.
    O'shea JC; Madan M; Cantor WJ; Pacchiana CM; Greenberg S; Joseph DM; Kitt MM; Lorenz TJ; Tcheng JE
    Am Heart J; 2000 Dec; 140(6):834-9. PubMed ID: 11099985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Eptifibatide in patients with percutaneous coronary intervention in clinical practice. Results of a prospective registry].
    Zeymer U; Zahn R; Siegler KE; Senges J
    Herz; 2004 Nov; 29(7):651-5. PubMed ID: 15580318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention.
    Marmur JD; Poludasu S; Agarwal A; Vladutiu P; Feit A; Lapin R; Cavusoglu E
    J Invasive Cardiol; 2006 Nov; 18(11):521-6. PubMed ID: 17090813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Single-center experience with the Palmaz-Schatz intracoronary stent: the immediate results and medium- and long-term follow-up].
    Galassi AR; Tamburino C; Grassi R; Monaco A; Russo G; Ierna SM; Calvi V; Giuffrida G
    Cardiologia; 1996 Nov; 41(11):1097-105. PubMed ID: 9064207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.
    Lancet; 1997 May; 349(9063):1422-8. PubMed ID: 9164315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescue percutaneous coronary intervention using transradial arterial access with glycoprotein IIb/IIIa inhibitor eptifibatide therapy initiated post-fibrinolysis.
    Charlat ML
    J Invasive Cardiol; 2000 Dec; 12 Suppl D():13D-5D. PubMed ID: 11156716
    [No Abstract]   [Full Text] [Related]  

  • 16. Immediate and intermediate results of intracoronary stand-alone bolus administration of eptifibatide during coronary intervention (ICE) study.
    Hassan W; Al-Sergani H; Al Buraiki J; Dunn B; Al Turki F; Akhras N; Elshaer F; Nawaz M; Kharabsheh S; ElKum N
    Am Heart J; 2007 Aug; 154(2):345-51. PubMed ID: 17643587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Latin American randomized trial of balloon angioplasty vs coronary stenting for small vessels (LASMAL): immediate and long-term results.
    Rodriguez A; Rodríguez Alemparte M; Fernández Pereira C; Sampaolesi A; da Rocha Loures Bueno R; Vigo F; Obregón A; Palacios IF;
    Am J Med; 2005 Jul; 118(7):743-51. PubMed ID: 15989908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Gurbel PA; Bliden KP; Zaman KA; Yoho JA; Hayes KM; Tantry US
    Circulation; 2005 Mar; 111(9):1153-9. PubMed ID: 15738352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of intracoronary eptifibatide bolus only versus intracoronary bolus and intravenous infusion of eptifibatide in primary percutaneous coronary intervention.
    Soon D; Ho HH; Loh KK; Ooi YW; Foo D; Jafary FH; Ong PJ
    Acute Card Care; 2012 Mar; 14(1):42-4. PubMed ID: 22273457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions.
    Fischell TA; Attia T; Rane S; Salman W
    J Invasive Cardiol; 2006 Oct; 18(10):487-91. PubMed ID: 17042093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.